Pharmaceutical is part of our work in Life Sciences.
People rely on the pharmaceutical industry for life-saving drugs and treatments, as well as those that improve the quality of life. Even with billions of dollars invested in research and development, few drugs make it through clinical trials and stringent regulatory clearances necessary to get to market. For those that do, it is crucial that the companies have protected the intellectual property (IP) underlying new drugs and treatments. Finnegan has a long history of working with innovative pharmaceutical companies to protect and maximize their valuable IP rights and assets, strategizing prosecution pathways and portfolio planning.
Our clients’ business and IP assets are global; protecting these assets across jurisdictions is increasingly challenging. With offices around the world and experience with multinational companies, Finnegan has the resources and experience to formulate and execute global strategies for pharmaceutical companies. The fast pace of new discoveries and their commercial applications require a comprehensive grasp of the IP legal issues and the industry insight to understand the scientific and strategic implications of the advancements.
With experience addressing virtually every type of IP issue for our pharmaceutical clients, we help by:
We work with clients innovating and advancing science in myriad fields, including:
Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.
Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.
Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.
Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.
Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.
Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer.
At the PTAB Blog
Squires Issues Precedential Decision Clarifying Obviousness-Type Double Patenting Rejections
August 17, 2026
Federal Circuit IP Blog
July 8, 2026
Award/Ranking
Partner Jeffrey M. Jacobstein Named Finalist for New England Legal Awards
August 10, 2026
Award/Ranking
Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards
July 15, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.